Your Messages Inbox
Your Article Summary
See Latest ArticlesKing Pharmaceuticals Offers New Dosage Strengths of Avinza to Provide More Treatment Options for People With Chronic Pain
King Pharmaceuticals, 02/06/09
King Pharmaceuticals, Inc. announced the launch of two new FDA-approved dosage strengths for AVINZA. The new dosing strengths, 45mg and 75mg, complement the currently available 30mg, 60mg, 90mg and 120mg dosages. AVINZA is a long-acting opioid for patients with moderate to severe chronic pain who require around-the-clock pain relief for an extended period of time.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Gilead and GlaxoSmithKline Announce Agreement to Commercialize Viread(R) for Chronic Hepatitis B in Key Asian Countries
Gilead, 11/25/09
Boston Scientific Announces FDA Clearance and CE Mark for WallFlex Fully Covered Esophageal Stent
Boston Scientific, 11/24/09
AstraZeneca submits US New Drug Application for ticagrelor, an investigational antiplatelet agent
AstraZeneca, 11/23/09
Today in Marketing/Media/ROI...keeping you current
Receive free subspecialty "5-minute updates" via email
Chugai Revises Corporate Advertisement for First Time in Four Years
Chugai Pharmaceutical Co., 11/25/09
Boston Scientific Announces FDA Clearance and CE Mark for WallFlex Fully Covered Esophageal Stent
Boston Scientific, 11/24/09
Medtronic Introduces 3D Recon Service to Enhance Endovascular Treatment of Aortic Aneurysms
Medtronic, 11/20/09
Article Search
Sponsor